Thursday, November 27, 2014

Best Warren Buffett Companies To Own In Right Now

Best Warren Buffett Companies To Own In Right Now: DARA Biosciences Inc.(DARA)

DARA BioSciences, Inc., a development stage biopharmaceutical company, engages in the development and commercialization of oncology treatment and supportive care pharmaceutical products in the United Sates. Its products include Soltamox for the treatment of breast cancer; Gemcitabine for first-line therapy for ovarian, breast, lung and pancreatic cancers; and other cancer support therapeutics, as well as generic sterile injectable cytotoxic products. Its drug development programs include KRN5500, a non-narcotic/non-opioid that has completed Phase IIa clinical trial for the treatment of neuropathic pain in cancer patients; and DB959, which has completed a Phase I study for the treatment of metabolic diseases, including type 2 diabetes and dyslipidemia. The company?s pre-clinical drug candidate includes DB900 PPAR gamma/alpha/delta agonists for development in metabolic and inflammatory diseases; DB160, DPPIV enzyme inhibitors with applications in diabetes, stem cell transpl antation, and cancer therapy; and DB200, Carnitine palmitoyltransferase-1 for skin diseases, including psoriasis. DARA BioSciences, Inc. was incorporated in 2002 and is headquartered in Raleigh, North Carolina.

Advisors' Opinion:
  • [By Lisa Levin]

    DARA BioSciences (NASDAQ: DARA) shares fell 15.02% to touch a new 52-week low of $1.81. DARA BioSciences' trailing-twelve-month ROA is -66.74%.

    LCNB (NASDAQ: LCNB) shares touched a new 52-week low of $16.57. LCNB shares have dropped 4.80% over the past 52 weeks, while the S&P 500 index has gained 18.57% in the same period.

  • [By John Kell and Lauren Pollock var popups = dojo.query(".socialByline .popC"); ]

    Dara Biosciences Inc.(DARA) signed a Medicare Part D prescription drug reimbursement agreement with Wellcare He! alth Plans Inc.(WCG), providing its Soltamox breast-cancer drug with access to the managed-care company’s extensive network. The pharmaceutical company’s shares rose 19% to $3.45 premarket.

  • [By Bryan Murphy]

    Without knowing the whole story, it would be easy to dismiss the big 9% jump from DARA Biosciences Inc. (NASDAQ:DARA) today as nothing more than a little volatility.... bullishness that wasn't destined to linger, especially considering how ugly the market turned in Monday's trading. As is always the case, though, with DARA, there's more to the story. Today's move may well be the official beginning of a much bigger, trade-worthy rally.

  • source from Top Stocks For 2015:

No comments:

Post a Comment